Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: tsigprofit who wrote (10222)	1/14/2003 11:05:18 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

Thanks to all for the kind thoughts... ARIA has patent news> Business Wire - January 14, 2003 10:28 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 14, 2003--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the issuance of a U.S. patent covering intramuscular administration of therapeutic genes controlled by ARIAD's cell-signaling regulation technology - the product concept being used in ARIAD's novel erythropoietin (EPO) anemia product candidate. A specially designed, dormant form of the EPO gene is injected into muscle at the onset of treatment, followed by oral administration of ARIAD's patented, small molecule-drug, AP22594, once or twice a month, to increase circulating levels of EPO and red blood cells directly in proportion to the amount of AP22594 administered. "This newly issued patent further strengthens our intellectual property portfolio for orally regulated protein therapy and specifically covers our novel EPO product candidate to treat anemia. This patent brings together the key elements of regulated protein therapy: our ARGENT technology for gene regulation, our AAV gene delivery vehicle, and the choice of muscle as the site of gene delivery," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.